These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

289 related articles for article (PubMed ID: 37765064)

  • 1. Non-Anticoagulant Activities of Low Molecular Weight Heparins-A Review.
    Feng K; Wang K; Zhou Y; Xue H; Wang F; Jin H; Zhao W
    Pharmaceuticals (Basel); 2023 Sep; 16(9):. PubMed ID: 37765064
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Low molecular weight heparins and their clinical applications.
    Hao C; Sun M; Wang H; Zhang L; Wang W
    Prog Mol Biol Transl Sci; 2019; 163():21-39. PubMed ID: 31030749
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An update on heparins at the beginning of the new millennium.
    Fareed J; Hoppensteadt DA; Bick RL
    Semin Thromb Hemost; 2000; 26 Suppl 1():5-21. PubMed ID: 11011802
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Determination of sulfation degree of heparin and low molecular weight heparins by capillary electrophoresis].
    Shen Y; Kang J
    Se Pu; 2020 Oct; 38(10):1238-1242. PubMed ID: 34213122
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Non-anticoagulant effects of low molecular weight heparins in inflammatory disorders: A review.
    Yan Y; Ji Y; Su N; Mei X; Wang Y; Du S; Zhu W; Zhang C; Lu Y; Xing XH
    Carbohydr Polym; 2017 Mar; 160():71-81. PubMed ID: 28115102
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Heparin, low-molecular-weight heparins, and heparin pentasaccharide: basic and clinical differentiation.
    Hoppensteadt D; Walenga JM; Fareed J; Bick RL
    Hematol Oncol Clin North Am; 2003 Feb; 17(1):313-41. PubMed ID: 12627673
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Determination of the anticoagulant activity of low molecular weight heparins by micellar electrokinetic chromatography combined with on-column enzymatic reaction].
    Zhang M; Kang J
    Se Pu; 2020 Oct; 38(10):1243-1248. PubMed ID: 34213123
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety profile of different low-molecular weight heparins used at therapeutic dose.
    Gouin-Thibault I; Pautas E; Siguret V
    Drug Saf; 2005; 28(4):333-49. PubMed ID: 15783242
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Management of thrombotic and cardiovascular disorders in the new millenium.
    Fareed J; Hoppensteadt DA; Bick RL
    Clin Appl Thromb Hemost; 2003 Apr; 9(2):101-8. PubMed ID: 12812377
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative effectiveness of low-molecular-weight heparins versus other anticoagulants in major orthopedic surgery: a systematic review and meta-analysis.
    Sobieraj DM; Coleman CI; Tongbram V; Chen W; Colby J; Lee S; Kluger J; Makanji S; Ashaye A; White CM
    Pharmacotherapy; 2012 Sep; 32(9):799-808. PubMed ID: 22744711
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Controllable production of low molecular weight heparins by combinations of heparinase I/II/III.
    Wu J; Zhang C; Mei X; Li Y; Xing XH
    Carbohydr Polym; 2014 Jan; 101():484-92. PubMed ID: 24299802
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Low-molecular-weight heparins in thrombosis and cancer: emerging links.
    Mousa SA
    Cardiovasc Drug Rev; 2004; 22(2):121-34. PubMed ID: 15179449
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Product individuality of commercially available low-molecular-weight heparins and their generic versions: therapeutic implications.
    Maddineni J; Walenga JM; Jeske WP; Hoppensteadt DA; Fareed J; Wahi R; Bick RL
    Clin Appl Thromb Hemost; 2006 Jul; 12(3):267-76. PubMed ID: 16959680
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tinzaparin and other low-molecular-weight heparins: what is the evidence for differential dependence on renal clearance?
    Johansen KB; Balchen T
    Exp Hematol Oncol; 2013; 2():21. PubMed ID: 23927414
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Overview of low molecular weight heparins and heparinoids: basic and clinical aspects.
    Hirsh J
    Aust N Z J Med; 1992 Oct; 22(5):487-95. PubMed ID: 1280097
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anticoagulant activity and pleiotropic effects of heparin.
    Bal Dit Sollier C; Dillinger JG; Drouet L
    J Med Vasc; 2020 May; 45(3):147-157. PubMed ID: 32402428
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Low molecular weight heparins.
    Bergqvist D
    J Intern Med; 1996 Aug; 240(2):63-72. PubMed ID: 8810931
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anticoagulation for the long-term treatment of venous thromboembolism in people with cancer.
    Kahale LA; Hakoum MB; Tsolakian IG; Matar CF; Terrenato I; Sperati F; Barba M; Yosuico VE; Schünemann H; Akl EA
    Cochrane Database Syst Rev; 2018 Jun; 6(6):CD006650. PubMed ID: 29920657
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Production and chemical processing of low molecular weight heparins.
    Linhardt RJ; Gunay NS
    Semin Thromb Hemost; 1999; 25 Suppl 3():5-16. PubMed ID: 10549711
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Generic low-molecular-weight heparins: some practical considerations.
    Fareed J; Leong WL; Hoppensteadt DA; Jeske WP; Walenga J; Wahi R; Bick RL
    Semin Thromb Hemost; 2004 Dec; 30(6):703-13. PubMed ID: 15630677
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.